schizophrenia

Teva to market Alexza agitation treatment in the U.S.

Teva to market Alexza agitation treatment in the U.S.

Reuters

Targacept moving forward with trials for schizophrenia treatment

Targacept moving forward with trials for schizophrenia treatment

Winston-Salem Journal, NC

Pipeline Setback at BioLineRx

Pipeline Setback at BioLineRx

Yahoo/Zacks

BioLineRx Shares Fall On Schizophrenia Drug Failure

BioLineRx Shares Fall On Schizophrenia Drug Failure

TheStreet.com

Vanda pulls EU filing for schizophrenia drug

Vanda pulls EU filing for schizophrenia drug

Pharma Times, UK

Otsuka, Lundbeck Win Approval for Monthly Abilify Shot

Otsuka, Lundbeck Win Approval for Monthly Abilify Shot

Bloomberg

Otsuka Can Block Generic Abilify as Court Rejects Appeal

Otsuka Can Block Generic Abilify as Court Rejects Appeal

Bloomberg

Alkermes Aims for Psychiatric Drug That Won’t Pack on the Pounds

Alkermes Aims for Psychiatric Drug That Won’t Pack on the Pounds

Xconomy

Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

Yahoo

Alexza's agitation drug gets FDA approval

Alexza's agitation drug gets FDA approval

Reuters